PURPOSE OF REVIEW: Current risk stratification and treatment decision-making for bladder cancer informed by histopathology as well as molecular diagnostics face limitations. This review summarizes recent advancements in single-cell and spatial omics methodologies for understanding bladder cancer biology and their potential impact on development of novel therapeutic strategies. RECENT FINDINGS: Single-cell RNA sequencing and spatial omics techniques offer unprecedented insights into various aspects of tumor microenvironment (TME), bladder cancer heterogeneity, cancer stemness, and cellular plasticity. Studies have identified multiple malignant cell subpopulations within tumors, revealing diverse transcriptional states and clonal evolution. Additionally, intratumor heterogeneity has been linked to tumor progression and therapeutic response. Immune cell composition analysis has revealed immunosuppressive features in the TME, impacting treatment response. Furthermore, studies have elucidated the role of cancer-associated fibroblasts and endothelial cells in shaping the tumor immune landscape and response to therapy. SUMMARY: Single-cell and spatial omics technologies have revolutionized our understanding of bladder cancer biology, uncovering previously unseen complexities. These methodologies provide valuable insights into tumor heterogeneity and microenvironmental interactions, with implications for therapeutic development. However, challenges remain in translating research findings into clinical practice and implementing personalized treatment strategies. Continued interdisciplinary collaboration and innovation are essential for overcoming these challenges and leveraging the full potential of single-cell and spatial omics in improving bladder cancer diagnosis and treatment.

Center for Cancer Research and Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology and Comprehensive Cancer Center

Department of Urology University of Texas Southwestern Dallas Texas USA

Department of Urology Weill Cornell Medical College New York New York

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Research Center for Evidence Medicine Urology Department Tabriz University of Medical Sciences Tabriz Iran

See more in PubMed

Zhang Y, Rumgay H, Li M, et al. . The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health 2023; 13:04109. PubMed PMC

Meeks JJ, Al-Ahmadie H, Faltas BM, et al. . Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol 2020; 17:259–270. PubMed PMC

Lai H, Cheng X, Liu Q, et al. . Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer. Int J Cancer 2021; 149:2099–2115. PubMed

Chen Z, Chen D, Song Z, et al. . Mapping the tumor microenvironment in bladder cancer and exploring the prognostic genes by single-cell RNA sequencing. Front Oncol 2022; 12:1105026. PubMed PMC

Jin X, Wang Q, Luo F, et al. . Single-cell transcriptomic analysis of tumor heterogeneity and intercellular networks in human urothelial carcinoma. Chin Med J (Engl) 2023; 136:690–706. PubMed PMC

Schallenberg S, Dragomir MP, Anders P, et al. . Intratumoral heterogeneity of molecular subtypes in muscle-invasive bladder cancer: an extensive multiregional immunohistochemical analysis. Eur Urol Focus 2023; 9:788–798. PubMed

Lindskrog SV, Schmokel SS, Nordentoft I, et al. . Single-nucleus and spatially resolved intratumor subtype heterogeneity in bladder cancer. Eur Urol Open Sci 2023; 51:78–88. PubMed PMC

Lindskrog SV, Prip F, Lamy P, et al. . An integrated multiomics analysis identifies prognostic molecular subtypes of nonmuscle-invasive bladder cancer. Nat Commun 2021; 12:2301. PubMed PMC

Kamoun A, de Reynies A, Allory Y, et al. . A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 2020; 77:420–433. PubMed PMC

Van Wart AT, Durrant J, Votapka L, Amaro RE. Weighted implementation of suboptimal paths (WISP): an optimized algorithm and tool for dynamical network analysis. J Chem Theory Comput 2014; 10:511–517. PubMed PMC

Zhou R, Liang J, Chen Q, et al. . Development and validation of an intra-tumor heterogeneity-related signature to predict prognosis of bladder cancer: a study based on single-cell RNA-seq. Aging (Albany NY) 2021; 13:19415–19441. PubMed PMC

Li Y, Xu X, Song L, et al. . Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. Gigascience 2012; 1:12. PubMed PMC

Yang Z, Li C, Fan Z, et al. . Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells. Eur Urol 2017; 71:8–12. PubMed

Wang H, Mei Y, Luo C, et al. . Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer. Clin Cancer Res 2021; 27:6265–6278. PubMed

Guo W, Keckesova Z, Donaher JL, et al. . Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012; 148:1015–1028. PubMed PMC

Li T, Huang H, Shi G, et al. . TGF-beta1-SOX9 axis-inducible COL10A1 promotes invasion and metastasis in gastric cancer via epithelial-to-mesenchymal transition. Cell Death Dis 2018; 9:849. PubMed PMC

Ma L, Chen H, Yang W, Ji Z. Crosstalk between mesenchymal stem cells and cancer stem cells reveals a novel stemness-related signature to predict prognosis and immunotherapy responses for bladder cancer patients. Int J Mol Sci 2023; 24:4760. PubMed PMC

Biswas A, Sahoo S, Riedlinger GM, et al. . Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma. Commun Biol 2023; 6:1292. PubMed PMC

Sfakianos JP, Daza J, Hu Y, et al. . Epithelial plasticity can generate multilineage phenotypes in human and murine bladder cancers. Nat Commun 2020; 11:2540. PubMed PMC

Warrick JI, Hu W, Yamashita H, et al. . FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nat Commun 2022; 13:6575. PubMed PMC

Sirab N, Drubay D, Maille P, et al. . Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. J Pathol 2022; 256:108–118. PubMed

Chen Z, Zhou L, Liu L, et al. . Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun 2020; 11:5077. PubMed PMC

Luo Y, Tao T, Tao R, et al. . Single-cell transcriptome comparison of bladder cancer reveals its ecosystem. Front Oncol 2022; 12:818147. PubMed PMC

Zhang Q, Zhang W, Lin T, et al. . Mass cytometry reveals immune atlas of urothelial carcinoma. BMC Cancer 2022; 22:677. PubMed PMC

Wang X, Pan L, Lu Q, et al. . A combination of ssGSEA and mass cytometry identifies immune microenvironment in muscle-invasive bladder cancer. J Clin Lab Anal 2021; 35:e23754. PubMed PMC

Oh DY, Kwek SS, Raju SS, et al. . Intratumoral CD4(+) T cells mediate antitumor cytotoxicity in human bladder cancer. Cell 2020; 181:1612–1625. e13. PubMed PMC

Patwardhan MV, Mahendran R. The bladder tumor microenvironment components that modulate the tumor and impact therapy. Int J Mol Sci 2023; 24:12311. PubMed PMC

Zheng H, An M, Luo Y, et al. . PDGFRalpha(+)ITGA11(+) fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. Cancer Cell 2024; 42:682–700. e12. PubMed

Ma Z, Li X, Mao Y, et al. . Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell 2022; 40:1550–1565. e7. PubMed

Li DX, Feng DC, Shi X, et al. . Identification of endothelial-related molecular subtypes for bladder cancer patients. Front Oncol 2023; 13:1101055. PubMed PMC

Freshour SL, Chen TH, Fisk B, et al. . Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer. iScience 2023; 26:107937. PubMed PMC

Wang M, Chen X, Tan P, et al. . Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell 2022; 40:1044–1059. e8. PubMed

Tanaka N, Katayama S, Reddy A, et al. . Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63. Cancer Med 2018; 7:6193–6204. PubMed PMC

Gouin KH, 3rd, Ing N, Plummer JT, et al. . An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. Nat Commun 2021; 12:4906. PubMed PMC

Lee HW, Chung W, Lee HO, et al. . Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med 2020; 12:47. PubMed PMC

Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. . Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019; 381:2020–2031. PubMed

Li H, Chen J, Li Z, et al. . S100A5 attenuates efficiency of Anti-PD-L1/PD-1 immunotherapy by inhibiting CD8(+) T cell-mediated anti-cancer immunity in bladder carcinoma. Adv Sci (Weinh) 2023; 10:e2300110. PubMed PMC

Wang L, Sfakianos JP, Beaumont KG, et al. . Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing. Clin Cancer Res 2021; 27:4287–4300. PubMed PMC

Robertson AG, Meghani K, Cooley LF, et al. . Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat Commun 2023; 14:2126. PubMed PMC

Liu L, Hou Y, Deng C, et al. . Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment. Nat Commun 2022; 13:6740. PubMed PMC

Guo R, Wang L, Bai S, et al. . Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis. Sci Rep 2023; 13:12801. PubMed PMC

Ouyang Y, Ou Z, Zhong W, et al. . FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation. Cancer Res 2023; 83:4030–4046. PubMed PMC

Song Y, Peng Y, Qin C, et al. . Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. J Immunother Cancer 2023; 11:e006643. PubMed PMC

Platten M, Nollen EAA, Rohrig UF, et al. . Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov 2019; 18:379–401. PubMed

Zhou G, Qin G, Zhang Z, et al. . Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma. Front Immunol 2023; 14:1283792. PubMed PMC